Loading
A phase 3 trial testing TQB2102 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06561607, led by Chia Tai Tianqing Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer. Planned enrolment is 542 participants (estimated). The study started in 2024-10-11 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing), HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.